Biomarin Pharmaceutical (BMRN) EBT (2017 - 2025)
Historic EBT for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to -$26.3 million.
- Biomarin Pharmaceutical's EBT fell 11958.03% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $679.3 million, marking a year-over-year increase of 7352.67%. This contributed to the annual value of $541.8 million for FY2024, which is 18731.14% up from last year.
- According to the latest figures from Q3 2025, Biomarin Pharmaceutical's EBT is -$26.3 million, which was down 11958.03% from $297.9 million recorded in Q2 2025.
- Biomarin Pharmaceutical's 5-year EBT high stood at $297.9 million for Q2 2025, and its period low was -$66.6 million during Q4 2021.
- Its 5-year average for EBT is $69.2 million, with a median of $41.7 million in 2023.
- As far as peak fluctuations go, Biomarin Pharmaceutical's EBT soared by 228849.79% in 2023, and later plummeted by 11958.03% in 2025.
- Quarter analysis of 5 years shows Biomarin Pharmaceutical's EBT stood at -$66.6 million in 2021, then surged by 73.63% to -$17.6 million in 2022, then surged by 210.08% to $19.3 million in 2023, then soared by 777.73% to $169.6 million in 2024, then plummeted by 115.52% to -$26.3 million in 2025.
- Its last three reported values are -$26.3 million in Q3 2025, $297.9 million for Q2 2025, and $238.1 million during Q1 2025.